I think to summarize, it is important to consider that Yost will build one single hand held device. That device will consist of a FAIMS-MS internal detection system. The exterior will likely be the same as well, it will have a spit separation port and other features that all only gas to pass through the injection port of the FAIMS-MS. I.e. only has molecules enter, thus no contamination by saliva. Straight forward. This external portion (the non-FAIMS stuff) comes from the Alpha device. These guys basically took Alpha and work FAIMS into it. As a result, they get something new that we don't call Beta, because it's not just an extension of Alpha anymore. We generate a new patent and IP.
The device, when completed (... likely not for a while), is going to be the exact same for both companies. They simply set the detection window (i.e the mass to charge ration of the gas molecules of interest will have a unique number... THC is different than a liver biomarker...) and thus it can be used for two different purposes.
Breathtec and Cannabix, thus license the technology from Yost individually. Maybe you find this strange? So do I. I have not quite figured out yet how Cannabix can license the patent that Breathtec needs to use also.
One thing is for sure. They have two companies, and will make twice the money, selling the same device, just for two different purposes. The ONLLY positive I see is that it makes sense that they wouldn't to want to mix drugs and medicine in the same sentence. THC detection and medical use need to be separate. You wouldn't go into a doctors office and use a THC breathalyzer. They just label it differently.
What's the downside. These guys take 7.5 million shares upon building the device and submitting the patent. WE GET DILUTED AGAIN. And guess what THEY MAKE MORE FROM BREATHTEC FOR BUILDING THE SAME DEVICE.
These guys are going to dilute us again here shortly.
News 
Market Data 
Discover 
